Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $4M (down 95.0% year over year) with net income of −$45M.
Q1 2026 key financials · XBRL
- Revenue
- $4M
- −95.0% YoY
- Net income
- −$45M
- −194.9% YoY
- Operating margin
- -1188.5%
Source: XBRL data from the Monte Rosa Therapeutics, Inc. (GLUE) Q1 2026 10-Q on SEC EDGAR. USD.
Monte Rosa Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes identifiable; provided text is truncated before the Risk Factors section
- Liquidity risk: accumulated deficit $521.7 million and additional funding needed beyond cash, cash equivalents, and marketable securities of $666.2 million
- Collaboration concentration risk: Roche agreement termination rights permit country-by-country or target-by-target termination
- Clinical and regulatory risk: product candidates require extensive preclinical and clinical testing plus regulatory approval before commercialization
- Operating loss risk: net loss $44.5 million in Q1 2026, with losses and negative operating cash flows expected to continue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monte Rosa Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.